Shares of Apellis Pharmaceuticals Inc. gained 5.1% in premarket trading on Friday after it shared details from a late-stage clinical trial evaluating its experimental drug pegcetacoplan against Alexion Pharmaceuticals Inc.'s Soliris as a treatment for paroxysmal nocturnal hemoglobinuria. The study found that pegcetacoplan was better than Soliris in improving hemoglobin levels in adults with the rare blood disease. Soliris brought in $3.9 billion in revenue in 2019. Apellis said it plans to submit a new drug application for pegcetacoplan to the Food and Drug Administration in the second half of the year. Its stock is down 0.5% year-to-date, while the S&P 500 has declined 7.1%.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Jack Fincham sends fans wild as he poses with his lookalike baby in rare snapJack Fincham, 29, took to Instagram to share the rare snap of his five-and-a-half month old baby girl he shares with ex Casey Ranger
Read more »
Kelly Clarkson Files For Divorce From Brandon Blackstock After Nearly 7 Years Of MarriageThe couple share two children together, daughter River Rose and son Remington Alexander.
Read more »
Minneapolis police are rarely disciplined for complaints, records showMinneapolis police officers who face complaints are rarely held accountable, a CNN investigation shows. Around 97% of the time, officers are not disciplined.
Read more »